









Markets
/
Stocks
/
nasdaq-pmcb
/

PharmaCyte Biotech Inc

PMCB

0.705USD

-0.075-9.64%

Market hours （ET）Quotes delayed by 15 min

175.47KMarket Cap

LossP/E TTM



PharmaCyte Biotech Inc

0.705

-0.075-9.64%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of PharmaCyte Biotech Inc

Currency: USD Updated: 2026-03-27

Key Insights

PharmaCyte Biotech Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 206 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

PharmaCyte Biotech Inc's Score

Industry at a Glance

Industry Ranking

206 / 391

Overall Ranking

403 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

PharmaCyte Biotech Inc Highlights

StrengthsRisks

PharmaCyte Biotech, Inc. is a biotechnology company, which is focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Fairly Valued

The company’s latest PE is -0.80, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 434.85K shares, decreasing 46.71% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 94.04K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 4.02.

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of PharmaCyte Biotech Inc is 6.98, ranking 152 out of 391 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.98

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.29

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.50

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.11

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

PharmaCyte Biotech Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of PharmaCyte Biotech Inc is 7.13, ranking 164 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.80, which is -2853.62% below the recent high of 21.89 and -1706.20% above the recent low of -14.36.

Score

Industry at a Glance

Previous score

7.13

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 206/391

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

No earnings forecast score is currently available for PharmaCyte Biotech Inc. The Biotechnology & Medical Research industry's average is 8.07.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of PharmaCyte Biotech Inc is 7.03, ranking 95 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 0.82 and the support level at 0.61, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.91

Change

-1.88

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

0.019

Neutral

RSI(14)

47.727

Neutral

STOCH(KDJ)(9,3,3)

53.446

Sell

ATR(14)

0.071

Low Volatility

CCI(14)

44.518

Neutral

Williams %R

62.857

Sell

TRIX(12,20)

0.047

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

0.750

Sell

MA10

0.723

Sell

MA20

0.709

Sell

MA50

0.754

Sell

MA100

0.802

Sell

MA200

0.902

Sell

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of PharmaCyte Biotech Inc is 3.00, ranking 195 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 4.29%, representing a quarter-over-quarter decrease of 36.25%. The largest institutional shareholder is James Simons, holding a total of 94.04K shares, representing 0.88% of shares outstanding, with 21.45% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Citadel Advisors LLC

14.53K

Schechter (Jonathan L)

132.50K

+165.00%

Geode Capital Management, L.L.C.

126.60K

Renaissance Technologies LLC

Star Investors

80.00K

+60.64%

The Vanguard Group, Inc.

Star Investors

74.92K

-61.47%

Weinstein (Robert)

41.25K

Northern Trust Investments, Inc.

19.21K

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of PharmaCyte Biotech Inc is 1.34, ranking 318 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 0.34. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.